drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T cells)
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting CD19; after infusion they eliminate CD19+ B-lineage cells, producing deep and sustained B-cell depletion and a potential immune reset.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD19 on B-lineage cells. Upon CD19 engagement, the CAR T cells activate and kill target B cells and plasmablasts via perforin/granzyme and death-receptor pathways, causing deep and sustained B-cell depletion, suppression of autoantibody production, and a potential immune reset. Activity is MHC-independent.
drug_name
Anti-CD19 CAR T cells
nct_id_drug_ref
NCT06508346